Patent extensions
This article was originally published in The Tan Sheet
Executive Summary
GAO report on potential delays in FDA's review of Schering-Plough's Rx antihistamine Claritin could be complete by July, Senate Judiciary Committee ranking minority member Patrick Leahy (D-Vt.) says June 27. Leahy joined Sens. Edward Kennedy (D-Mass.), Paul Wellstone (D-Minn.), Richard Durbin (D-Ill.) and James Jeffords (R-Vt.) in urging the removal of patent extension amendments currently included in must-pass bills. For instance, the Claritin extension is included in the military construction spending bill, currently in conference. The possibility of switching Schering-Plough's antihistamine was discussed at a recent FDA public meeting (1see story, p. 3)
You may also be interested in...
Rx Antihistamine Switch Consumer Cost Increases Unlikely, Insurer Tells FDA
Switching Rx low- and non-sedating, second-generation antihistamines over-the-counter is unlikely to increase out-of-pocket costs for U.S. consumers based upon OTC pricing of the drugs in foreign countries, a health insurance rep told FDA June 29.
Rx Antihistamine Switch Consumer Cost Increases Unlikely, Insurer Tells FDA
Switching Rx low- and non-sedating, second-generation antihistamines over-the-counter is unlikely to increase out-of-pocket costs for U.S. consumers based upon OTC pricing of the drugs in foreign countries, a health insurance rep told FDA June 29.
Rx Antihistamine Switch Consumer Cost Increases Unlikely, Insurer Tells FDA
Switching Rx low- and non-sedating, second-generation antihistamines over-the-counter is unlikely to increase out-of-pocket costs for U.S. consumers based upon OTC pricing of the drugs in foreign countries, a health insurance rep told FDA June 29.